ADAM10 and leukemia: We conclude that drugs inhibiting ADAM10 may have the potential to impair the leukemia-niche interaction and tumor maintenance in patients with leukemia, thereby reducing tumor burden, diminishing stem cells and increasing the effectiveness of conventional chemotherapy against leukemia.